Clinical Trial Update: Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 safety study of the HSP90 inhibitor IPI-504 in patients with relapsed and relapsed-refractory multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• IPI-504 (retaspimycin hydrochloride)

Snippet

Sponsor: Infinity Pharmaceuticals, Inc. | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED